• Pentixapharm presented data at the American Heart Association congress on November 11, 2026, supporting PentixaFor imaging without stopping blood pressure medication.
• An independent study of 41 patients found imaging agreement with invasive testing was similar with or without aldosterone-blocking treatment.
• The Phase 3 PANDA trial targets about 325 adults, with enrollment expected in the first quarter of 2027.
• PANDA will assess PentixaFor’s diagnostic accuracy for primary aldosteronism subtyping, including whether patients can continue medication during imaging.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.